

UMMC PAIN, SEDATION, AND DELIRIUM GUIDELINES FOR VENTILATED PATIENTS

All benzodiazepine continuous infusions must be approved by the Attending Physician and/or Fellow

- Initiate ABCDE approach for mechanically ventilated patients^a
- Optimize environment and treat pain first
- Assess pain using an objective assessment tool
- Include **RASS endpoint** in sedation orders (physician only)
- Titrate sedation to appropriate RASS score (RASS zero to -2)
- Reassess sedation goal daily
- Implement delirium prevention protocol
- Assess delirium using CAM-ICU at least twice daily
- AVOID medications that may alter mental status (e.g., diphenhydramine, anticholinergics)

Is patient comfortable and sedation at goal?

NO

YES

- Rule out and correct reversible causes (e.g. re-orientation, optimize environment, patient positioning)

- Perform SAT and SBT trials daily (refer to SAT and SBT protocol)
- Reassess sedation and analgesic requirements
- Maintain sedation goal with **minimal effective dose** of medications

Pain^b

YES

Analgesic Management

- First line: Fentanyl OR Hydromorphone OR Oxycodone (if enteral route available)
- Consider patient-controlled analgesia (PCA) after 48 hours of mechanical ventilation

Agitation^b
(RASS > +1)

YES

Sedation Management

- First-line: Optimize pain management (i.e., analgosedation)
- First-line for severe agitation (RASS \geq +2): Propofol^d
- Dexmedetomidine for the following appropriate indications:
 - 1) Adjuvant therapy for patients when clinicians are unable to maintain RASS between zero to -2 on propofol
 - 2) For patients who continue to require sedation when propofol inhibits progress toward extubation
- If agitation still not controlled, can use diazepam as needed for rescue therapy
- Avoid benzodiazepines EXCEPT in alcohol or benzodiazepine withdrawal management

Delirium^b
(CAM-ICU positive)

YES

Acute Delirium Management

- Identify causes & eliminate factors
- Consider Haloperidol^c IV or IM or Ziprasidone IM or PO until agitation controlled (if QTc < 500 msec)

Maintenance Delirium Management^c

- Optimize delirium prevention and use non-pharmacological therapies
 - 1) Intravenous (IV) option: Haloperidol (if QTc < 500 msec)
 - 2) Oral (PO) options: Quetiapine or Ziprasidone
 - 3) Intramuscular (IM) options: Haloperidol or Ziprasidone

Sleep
Disturbance^b

YES

Sleep Management

- Minimize ambient light, noise, and patient interruptions at night time (see other side for other strategies)
- If still not controlled, consider quetiapine

General Information

^a ABCDE: awakening and breathing coordination of daily sedation and ventilator removal trials, choice of sedative or analgesic exposure, delirium monitoring, and early mobility and exercise

^b Refer to other side for initial medication dosing recommendations. In presence of hepatic and/or renal impairment, dose adjustment should be considered

^c Obtain baseline QTc, then daily; Use lower doses in patients > 65 years old

^d Monitor triglyceride levels in patients receiving propofol for > 72 hours

Initial Medication Dosing Recommendations

Pain Therapy

- Fentanyl 25 – 50 mcg IV q 1 hr PRN or Scheduled or continuous infusion 25 – 300 mcg/hr
- Hydromorphone 0.5 – 1 mg q 2 hr IV PRN or Scheduled
- Oxycodone 5 – 10 mg q 4 to 6 hr PO PRN or Scheduled
- Acetaminophen 650 – 1000 mg q 4 to 6 hr PO PRN or Scheduled (max 4000 mg/day); monitor hepatic function

Agitation Therapy

- First line: Propofol 5 – 60 mcg/kg/min infusion (no loading dose or bolus)
- Second line: Dexmedetomidine 0.2 – 1.5 mcg/kg/hr infusion (no loading dose or bolus due to concern for hypotension or bradycardia); should not be used for deep sedation
- If no response to propofol or dexmedetomidine:
 - Diazepam 2 – 10 mg IV q 15 minutes until controlled for acute agitation
 - Midazolam 2 – 5 mg IV q 15 minutes until controlled for acute agitation or 1 – 2 mg IV q 1 to 2 hr for maintenance sedation
 - Lorazepam 1 – 4 mg IV q 2 to 4 hr PRN or ATC for maintenance sedation

Delirium Therapy

- Haloperidol 1 – 10 mg IV q 2 to 6 hr; consider starting at 1 – 2.5 mg/dose for elderly patients (age > 65 years)
- Quetiapine 25 – 50 mg PO q 12 hr (max 200 mg/day)
- Ziprasidone 20 – 80 mg PO q 12 hr (max 160 mg/day) or 10 mg IM q 2 to 4 hr (max 40 mg/day)
- When appropriate, please taper and discontinue antipsychotic therapy once delirium has resolved

Sleep Non-Pharmacologic Therapy

- Normalize sleep wake cycle: open blinds, use clocks, eyeglasses/hearing aids, reorientation, decrease ambient noise
- Aim for uninterrupted period of sleep at night
- Discourage naps

Richmond Agitation Sedation Scale (RASS)

Score	Term	Description	
+4	Combative	Overtly combative, violent, immediate danger to staff/self	
+3	Very agitated	Pulls or removes tube(s) or catheter(s); aggressive	
+2	Agitated	Frequent non-purposeful movement, fights ventilator	
+1	Restless	Anxious but movements not aggressive vigorous	
0	Alert and calm		
-1	Drowsy	Not fully alert, but has sustained awakening (eye opening/eye contact) to voice (≥ 10 seconds)	Verbal Stimulation
-2	Light sedation	Briefly awakens with eye contact to voice (< 10 seconds)	
-3	Moderate sedation	Movement or eye opening to voice (but no eye contact)	
-4	Deep sedation	No response to voice, but movement or eye opening to physical stimulation	Physical Stimulation
-5	Unarousable	No response to voice or physical stimulation	

Procedure for RASS Assessment

1. Observe patient
 - a. Patient is alert, restless, or agitated. (score 0 to +4)
2. If not alert, state patient's name and say to open eyes and look at speaker.
 - b. Patient awakens with sustained eye opening and eye contact. (score -1)
 - c. Patient awakens with eye opening and eye contact, but not sustained. (score -2)
 - d. Patient has any movement in response to voice but no eye contact. (score -3)
3. When no response to verbal stimulation, physically stimulate patient by shaking shoulder and/or rubbing sternum.
 - e. Patient has any movement to physical stimulation. (score -4)
 - f. Patient has no response to any stimulation. (score -5)